RT Journal Article
SR Electronic
T1 Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e007501
DO 10.1136/jitc-2023-007501
VO 12
IS 3
A1 Schadendorf, Dirk
A1 Luke, Jason John
A1 Ascierto, Paolo A
A1 Long, Georgina V
A1 Rutkowski, Piotr
A1 Khattak, Adnan
A1 Del Vecchio, Michele
A1 de la Cruz-Merino, Luis
A1 Mackiewicz, Jacek
A1 Sileni, Vanna Chiarion
A1 Kirkwood, John M
A1 Robert, Caroline
A1 Grob, Jean-Jacques
A1 Dummer, Reinhard
A1 Carlino, Matteo S
A1 Zhao, Yujie
A1 Kalabis, Mizuho
A1 Krepler, Clemens
A1 Eggermont, Alexander
A1 Scolyer, Richard A
YR 2024
UL http://jitc.bmj.com/content/12/3/e007501.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.